A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)

Trial Profile

A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Binimetinib (Primary) ; Pembrolizumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-651
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 12 Dec 2017 Status changed from planning to not yet recruiting.
    • 09 Aug 2017 According to an Array BioPharma media release, results from these and other study (CTP 285347) will be used to determine optimal approaches to further clinical development of the respective combinations.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top